Employees: 1,115
Size Chongqing Lummy Pharmaceutical (300006.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 1842nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.97 on 18 Nov 2026.
Performance Over six months the shares gained 25.9%, against -20.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue fell 6.2% over the last twelve months (peer median +7.6%); the operating margin is -18.6% (peer median 0.8%).
Valuation It trades at 10.4× enterprise value to sales against a peer median of 7.6× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +57 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 12.1 points below its cost of capital (6.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥720M | CN¥769M | CN¥785M | CN¥883M | CN¥874M |
| Revenue growth | — | -2% | -11% | +1% | — |
| Gross profit | CN¥394M | CN¥389M | CN¥466M | CN¥569M | CN¥593M |
| EBITDA | n/a | -CN¥47.7M | -CN¥66.9M | -CN¥32.8M | -CN¥72.5M |
| Net income | -CN¥119M | -CN¥135M | -CN¥87.8M | -CN¥8.93M | -CN¥68.7M |
| Free cash flow | CN¥40.4M | CN¥23.2M | CN¥146M | -CN¥46.9M | CN¥50.0M |
| Capital expenditure | CN¥30.6M | CN¥38.2M | CN¥75.5M | CN¥59.3M | CN¥68.2M |
| Total debt | CN¥358M | CN¥379M | CN¥495M | CN¥274M | CN¥365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300006.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.8% | -5.4% | 6th highest of 21 |
| 6-month return | +25.9% | -20.6% | 2nd highest of 21 |
| Distance from 52-week high | -37.1% | -41.7% | 10th highest of 21 |
| Revenue growth (TTM) | -6.2% | +7.6% | 5th lowest of 18 |
| Operating margin | -18.6% | 0.8% | 9th lowest of 18 |
| EV / Sales | 10.4× | 7.6× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 44.1% | 2.5% | most demanding of 6 |
| Growth delivered (Del g) | -13.2% | -1.3% | lowest of 6 |
| Hurdle (Req g minus delivered) | +57.3 pp | +1.0 pp | most demanding of 6 |
| ROIC minus cost of capital | -12.1 pp | -5.1 pp | 8th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |